Benitec Biopharma Inc. (BNTC)
- Previous Close
7.50 - Open
7.35 - Bid 5.40 x 200
- Ask 9.47 x 200
- Day's Range
7.34 - 7.55 - 52 Week Range
1.86 - 10.70 - Volume
23,184 - Avg. Volume
89,903 - Market Cap (intraday)
69.507M - Beta (5Y Monthly) 0.73
- PE Ratio (TTM)
-- - EPS (TTM)
-235.52 - Earnings Date May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.00
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
benitec.comRecent News: BNTC
Performance Overview: BNTC
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BNTC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BNTC
Valuation Measures
Market Cap
69.51M
Enterprise Value
55.72M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.00k
Price/Book (mrq)
6.04
Enterprise Value/Revenue
7.96k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-115.70%
Return on Equity (ttm)
-267.59%
Revenue (ttm)
7k
Net Income Avi to Common (ttm)
-21.69M
Diluted EPS (ttm)
-235.52
Balance Sheet and Cash Flow
Total Cash (mrq)
14.14M
Total Debt/Equity (mrq)
3.08%
Levered Free Cash Flow (ttm)
-11.91M